advertisement
Abstract #24046 Published in IGR 11-3
Antioxidant status modifications by topical administration of dorzolamide in primary open-angle glaucoma
Zanon-Moreno V; Garcia-Medina JJ; Gallego-Pinazo R; Vinuesa-Silva I; Moreno-Nadal MA; Pinazo-Duran MDEuropean Journal of Ophthalmology 2009; 19: 565-571
PURPOSE. This study deals with the role of the topical administration of dorzolamide eyedrops on the oxidative/antioxidant status of aqueous humor in patients with primary openangle glaucoma (POAG). METHODS. A case-control study including 130 patients distributed into three groups was carriedout: 1) patients with POAG without dorzolamide instillation administration (GG; n=34); 2) patients with POAG with dorzolamide (DG; n=36); and 3) subjects with cataracts (comparativegroup, CG; n=60). Oxidative activity was measured in the aqueous humor by malondialdehyde determination by the thiobarbituric acid reactive substances assay. Antioxidant status was assessed in the aqueous humor samples by measuring the superoxide dismutaseactivity and the total antioxidant status. RESULTS. Oxidative activity was significantly higher in both glaucoma groups than in the cataracts group (GG vs CG, p=3.68 E-34; DG vs CG, p=5.11 E-45) and was significantly higher in GG than in DG (p=0.0034). SOD activity was significantly higher in both glaucoma groups than in the cataracts group (GG vs CG, p=1.08 E-14; DG vs CG, p=3.70 E-22), and was significantly higher in GG than in DG (p=0.018). Finally, total antioxidant status was significantly decreased in both glaucoma groups compared with the cataracts group (GG vs CG, p=2.51 E-12; DG vs CG, p=5.06 E-05), and was more significantly decreased in GG than in DG (p=9.23 E-07). CONCLUSIONS. Topical administration of dorzolamide colirium diminishes oxidative stress in patients with glaucoma.
Dr. V. Zanon-Moreno, Ophthalmologic Research Unit "Santiago Grisolia," Dr. Peset University Hospital, Valencia, Spain
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
